An Experimental Study on the Evaluation of Boerhavia Diffusa in the Treatment of Psoriasis in Albino Mice
-
Published:2024-04-30
Issue:2
Volume:40
Page:506-513
-
ISSN:2231-5039
-
Container-title:Oriental Journal Of Chemistry
-
language:en
-
Short-container-title:Orient. J. Chem
Author:
Kumar Vinay1ORCID, Prajapati Pawan1ORCID, Goyal Gauri1ORCID, Rathore Virendra Pratap Singh2ORCID, Mishra Ashutosh3ORCID
Affiliation:
1. 1Department of Pharmacology, KIET Group of Institutions (KIET School of Pharmacy), Delhi-NCR, Meerut Road, Ghaziabad, (UP), India. 2. 2Department of Pharmacology, Maharana Pratap College of Pharmacy, Kanpur, (UP), India. 3. 3Mankind Research Center, 191 E sector 4 IMT Manesar, Gurgaon, Haryana, 122052 India.
Abstract
Psoriasis, impacting 2-3% of the population, poses a chronic challenge. Conventional treatments having limited effectiveness and adverse effects; recent immunological insights foster targeted therapies, while herbal medications gain attention for safety and accessibility. The current research aimed to assess the efficacy of Boerhavia diffusa in mitigating psoriasis induced by imiquimod in mice. Study induced psoriasis in albino mice using 5% imiquimod cream for 5 days, then treated with Boerhavia diffusa (1% and 3%) and Tazarotene (0.1%). Parameters were assessed in the study viz. PASI score, spleen weight/body weight ratio, serum inflammatory markers (IL-17, IL-23, and TNF-α), and skin histopathology. Mice treated with imiquimod exhibited noteworthy elevations in PASI score, spleen weight/body weight ratio, and serum inflammatory markers, which were effectively suppressed by Boerhavia diffusa and Tazarotene applications. Topically application of Boerhavia diffusa significantly ameliorated psoriasis, suggesting it as a promising, well-tolerated alternative to enhance the quality of life for affected individuals.
Publisher
Oriental Scientific Publishing Company
Reference30 articles.
1. 1. Mylonas, A.; Conrad, C. Front. immunol. 2018, 9, 2746. 2. 2. Lowes, M.A.; Suarez-Farinas, M.; Krueger, J.G. Annu. Rev. Immunol. 2014, 32, 227-255. 3. 3. Zeini, M.S.; Haddadi, N.S.; Shayan, M.; Zeini, M.S.; Kazemi, K.; Solaimanian, S.; Abdollahifar, M.A.; Hedayatyanfard, K.; Dehpour, A.R. Int. Immunopharmacol. 2021, 100, 108160. 4. 4. Li, Y.; Zhang, G.; Chen, M.; Tong, M.; Zhao, M.; Tang, F.; Xiao, R.; Wen, H. Biomed. Pharmacother. 2019, 109, 1876-1883. 5. 5. Nograles, K.E.; Krueger, J.G. Exp. Cell Res. 2011, 317, 1293-1300.
|
|